We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Novel Treatment for Aphasia and Apraxia of Speech : Measurement of Outcomes (AA: MoO)

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01979159
First Posted: November 8, 2013
Last Update Posted: September 22, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
VA Office of Research and Development
  Purpose

In order to determine if speech-language therapy has positive effect, reliable measurement tools are required to document outcomes. Currently, there is very limited information concerning the measurement of changes in speech production as a result of treatment for acquired apraxia of speech and aphasia. This study will obtain information concerning the reliability of several speech production measures over time. Thirty persons with chronic aphasia and apraxia of speech will be asked to provide speech samples in response to commonly used assessment tools on three sampling occasions so that the stability of measurements may be examined.

After establishment of appropriate outcome measures, a small, pilot treatment study will be conducted with four participants. The participants will receive a new treatment for aphasia and acquired apraxia of speech and outcomes will be measured relative to speech and language production.


Condition Intervention
Apraxia of Speech Aphasia Behavioral: Combined Aphasia and Apraxia of Speech Treatment (CAAST)

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Novel Treatment for Aphasia and Apraxia of Speech: Measurement of Outcomes

Resource links provided by NLM:


Further study details as provided by VA Office of Research and Development:

Primary Outcome Measures:
  • speech and language production [ Time Frame: Following completion of treatment; 3 sessions per week for 13-14 weeks ]
    production of connected speech/language in response to picture stimuli


Estimated Enrollment: 4
Actual Study Start Date: October 21, 2013
Estimated Study Completion Date: December 29, 2017
Primary Completion Date: December 30, 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Combined aphasia and apraxia of speech treatment (CAAST)
Administration of CAAST to 4 persons with aphasia and apraxia of speech in the context of single-subject designs
Behavioral: Combined Aphasia and Apraxia of Speech Treatment (CAAST)
Therapy is delivered in a face-to-face format. The therapist uses picture stimuli, verbal modeling, feedback, reinforcement, forward-chaining to increase verbal production. For speech errors that occur, the therapist uses modeling, feedback, reinforcement, simultaneous production, articulatory instruction, and repeated practice to improve articulation.
Other Name: CAAST

Detailed Description:

A single group, repeated measures design will be used to obtain repeated speech samples from 30 persons with chronic acquired apraxia of speech and aphasia. Speech samples will be elicited using commonly employed motor speech assessment protocols; an initial sample, a sample one week following the initial sample, and a sample at four weeks following the initial sample. The following measures will be obtained from the samples: percent consonants correct, percent fluent utterances, and duration of utterance. Stability of the measures will be examined.

After the preceding measures have been analyzed, a series of four, single-subject experimental designs will be conducted. Four participants with chronic aphasia and apraxia of speech will receive a new treatment for aphasia and apraxia of speech applied sequentially to two sets of experimental picture picture stimuli. Outcomes will be measured in terms of speech production (measures described above) as well as in terms of language production.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   21 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Veterans or non Veterans with aphasia and apraxia of speech who reside in the Salt Lake City region (commutable),
  • 12 months or more post stroke or other focal brain injury, no other neurological conditions,
  • native English speakers, hearing adequate for experimental task (e.g., pass puretone screening at 35dB at 500, 1K, 2K Hz),
  • non linguistic cognition within normal limits

Exclusion Criteria:

  • less than 12 months post stroke,
  • insufficient hearing, insufficient non linguistic cognitive skills,
  • neurological conditions other than stroke,
  • more than one stroke or brain injury
  • unable to attend treatment in the Salt Lake City vicinity
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01979159


Locations
United States, Utah
VA Salt Lake City Health Care System, Salt Lake City, UT
Salt Lake City, Utah, United States, 84148
Sponsors and Collaborators
VA Office of Research and Development
Investigators
Principal Investigator: Julie L Wambaugh, PhD VA Salt Lake City Health Care System, Salt Lake City, UT
  More Information

Publications:
Responsible Party: VA Office of Research and Development
ClinicalTrials.gov Identifier: NCT01979159     History of Changes
Other Study ID Numbers: O1356-P
First Submitted: October 23, 2013
First Posted: November 8, 2013
Last Update Posted: September 22, 2017
Last Verified: September 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by VA Office of Research and Development:
aphasia
apraxia of speech
outcomes

Additional relevant MeSH terms:
Aphasia
Apraxias
Speech Disorders
Language Disorders
Communication Disorders
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Psychomotor Disorders